www.perpetualcommotion.com
"Give with a free hand, but give only your own."
-- J.R.R. Tolkien The Children of Hurin
- Lithium -
General Information:
Names:
Wikipedia entry:
Dr. Ray Shahelien entry:
********************************************************************************************
Observations:
Lithium:
See also Tau Busters
********************************************************************************************
Known sources:
********************************************************************************************
Natural sources:
********************************************************************************************
References:
Lithium
Here is another take on the use of lithium:
I suggest reading the whole article, but here is an excerpt...
Taking (grey) matters into your own hands
"Hercule Poirot, Agatha Christie's famous fictional detective,
had an amusing quirk in his incessant concern for his "little
grey cells." I thought of Hercule several years ago when I saw
the following headline in an issue of the Lancet:
"Lithium-induced increase in human brain grey matter."
"That may not sound like an earth-shattering piece of news, but
it actually was quite a major discovery. To that point, medical
experts believed that once our brains matured, it was all
downhill from then on. Decades of autopsies, x-rays, and, more
recently, brain scans have repeatedly shown that brains shrink
measurably with aging. But according to their report in the
Lancet, Wayne State University (Detroit) researchers found that
lithium has the ability to both protect and renew brain cells.1
Eight of 10 individuals who took lithium showed an average 3
percent increase in brain grey matter in just four weeks.
"Lithium may help to generate entirely new cells too: Another
group of researchers recently reported that lithium also
enhances nerve cell DNA replication.2 DNA replication is a first
step in the formation of a new cell of any type.
"The Wayne State study used high-dose lithium, but I'm certainly
not using that amount myself, nor do I recommend it.
Prescription quantities of lithium just aren't necessary for
"everyday" brain cell protection and re-growth. Studies done
years ago have shown that very low amounts of lithium can also
measurably influence brain function for the better."
http://www.tahoma-clinic.com/lithium1.shtml
Inhibition of glycogen
synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration
in vivo
Proceedings of the National Academy of Sciences of the United
States
of America
PNAS | May 10, 2005 | vol. 102 | no. 19 | 6990-6995
"Neurofibrillary tangles composed of hyperphosphorylated,
aggregated tau are a common pathological feature of tauopathies,
including Alzheimer's disease. Abnormal phosphorylation of tau
by kinases or phosphatases has been proposed as a pathogenic
mechanism in tangle formation. To investigate whether kinase
inhibition can reduce tauopathy and the degeneration associated
with it in vivo, transgenic mice overexpressing mutant human tau
were treated with the glycogen synthase kinase-3 (GSK-3)
inhibitor lithium chloride. Treatment resulted in significant
inhibition of GSK-3 activity. Lithium administration also
resulted in significantly lower levels of phosphorylation at
several epitopes of tau known to be hyperphosphorylated in
Alzheimer's disease and significantly reduced levels of
aggregated, insoluble tau. Administration of a second GSK-3
inhibitor also correlated with reduced insoluble tau levels,
supporting the idea that lithium exerts its effect through GSK-3
inhibition. Levels of aggregated tau correlated strongly with
degree of axonal degeneration, and lithium-chloride-treated mice
showed less degeneration if administration was started during
early stages of tangle development. These results support the
idea that kinases are
involved in tauopathy progression and that kinase inhibitors may
be effective therapeutically."
http://www.pnas.org/cgi/content/abstract/102/19/6990?ck=nck
Lithium delays progression of
amyotrophic lateral sclerosis.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2052-7. Epub 2008
Feb 4
"ALS is a devastating neurodegenerative disorder with no
effective treatment. In the present study, we found that daily
doses of lithium, leading to plasma levels ranging from 0.4 to
0.8 mEq/liter, delay disease progression in human patients
affected by ALS. None of the patients treated with lithium died
during the 15 months of the follow-up, and disease progression
was markedly attenuated when compared with age-, disease
duration-, and sex-matched control patients treated with
riluzole for the same amount of time. In a parallel study on a
genetic ALS animal model, the G93A mouse, we found a marked
neuroprotection by lithium, which delayed disease onset and
duration and augmented the life span. These effects were
concomitant with activation of autophagy and an increase in the
number of the mitochondria in motor neurons and suppressed
reactive astrogliosis. Again, lithium reduced the slow necrosis
characterized by mitochondrial vacuolization and increased the
number of neurons counted in lamina VII that were severely
affected in saline-treated G93A mice. After lithium
administration in G93A mice, the number of these neurons was
higher even when compared with saline-treated WT. All these
mechanisms may contribute to the effects of lithium, and these
results offer a promising perspective for the treatment of human
patients affected by ALS."
http://www.pnas.org/cgi/reprint/105/6/2052
Lithium at 50: have the
neuroprotective effects of this unique cation been overlooked?
Biological Psychiatry. 1999 Oct 1;46(7):929-40. PMID: 10509176 [PubMed]
Manji HK, Moore GJ, Chen G.
Department of Psychiatry and Behavioral Neurosciences,
Wayne State University School of Medicine, Detroit, Michigan
48201, USA.
"Recent advances in cellular and molecular biology have resulted
in the identification of two novel, hitherto completely
unexpected targets of lithium's actions, discoveries that may
have a major impact on the future use of this unique cation in
biology and medicine. Chronic lithium treatment has been
demonstrated to markedly increase the levels of the major
neuroprotective protein, bcl-2 in rat frontal cortex,
hippocampus, and striatum. Similar lithium-induced increases in
bcl-2 are also observed in cells of human neuronal origin, and
are observed in rat frontal cortex at lithium levels as low as
approximately 0.3 mmol/L. Bcl-2 is widely regarded as a major
neuroprotective protein, and genetic strategies that increase
bcl-2 levels have demonstrated not only robust protection of
neurons against diverse insults, but have also demonstrated an
increase the regeneration of mammalian CNS axons. Lithium has
also been demonstrated to inhibit glycogen synthase kinase 3
beta (GSK-3 beta), an enzyme known to regulate the levels of
phosphorylated tau and beta-catenin (both of which may play a
role in the neurodegeneration observed in Alzheimer's disease).
Consistent with the increases in bcl-2 levels and inhibition of
GSK-3 beta, lithium has been demonstrated to exert robust
protective effects against diverse insults both in vitro and in
vivo. These findings suggest that lithium may exert some of its
long term beneficial effects in the treatment of mood disorders
via underappreciated neuroprotective effects. To date, lithium
remains the only medication demonstrated to markedly increase
bcl-2 levels in several brain areas; in the absence of other
adequate treatments, the potential efficacy of lithium in the
long term treatment of certain neurodegenerative disorders may
be warranted."
Rescuing Fruit Flies from
Alzheimer's Disease
ScienceDaily (July 16, 2010)
Investigators have found that fruit fly (Drosophila
melanogaster) males -- in which the activity of an Alzheimer's
disease protein is reduced by 50 percent -- show impairments in
learning and memory as they age. What's more, the researchers
were able to prevent the age-related deficits by treating the
flies with drugs such as lithium, or by genetic manipulations
that reduced nerve-cell signaling. The research team -- Thomas
A. Jongens, Ph.D., associate professor of Genetics at the
University of Pennsylvania School of Medicine; Sean M. J.
McBride M.D, Ph.D. and Thomas McDonald M.D., at the Albert
Einstein College of Medicine; and Catherine Choi M.D., Ph.D. at
Drexel University College of Medicine -- worked with the
familial form of Alzheimer's disease (FAD), an aggressive form
of the disease that is caused by mutations in one of the two
copies of the presenilin (PS) or amyloid precursor protein (APP)
genes. Studies in animal models have previously shown that the
FAD-linked PS mutations lead to less presenilin (psn) protein
activity. Their findings are published in the Journal of
Neuroscience...
http://www.sciencedaily.com/releases/2010/07/100715172014.htm
********************************************************************************************
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Home
Preface Brain Failure Notes Notes II
References pg. 1 References pg. 2
Nutritional Alternatives
Patricia's Protocol
Tauopathy
Discussion
Forum
Correspondence Newsletters Poems Memory Enhancement
********************************************************************************************
Questions or comments, contact "perpetualcommotion.com" at gmail.com
Updated: July 2, 2012
Inception: July 2, 2012